Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
A Plus Biotechnology Co's operating assets for the quarter that ended in Dec. 2025 was NT$940.6 Mil. A Plus Biotechnology Co's operating liabilities for the quarter that ended in Dec. 2025 was NT$188.3 Mil. A Plus Biotechnology Co's Total Assets for the quarter that ended in Sep. 2025 was NT$1,528.9 Mil. Therefore, A Plus Biotechnology Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.49.
A Plus Biotechnology Co Scaled Net Operating Assets Related Terms
A Plus Biotechnology Co Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for A Plus Biotechnology Co's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Plus Biotechnology Co Scaled Net Operating Assets Chart
TPE:6918 vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, A Plus Biotechnology Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.49 mean?
A Plus Biotechnology Co (TPE:6918) has a Scaled Net Operating Assets of 0.49 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on A Plus Biotechnology Co and its competitors.
Is A Plus Biotechnology Co's Scaled Net Operating Assets too high?
A Plus Biotechnology Co's current Scaled Net Operating Assets is 0.49. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Scaled Net Operating Assets compare to ABT and SYK?
A Plus Biotechnology Co's Scaled Net Operating Assets of 0.49 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on A Plus Biotechnology Co and its competitors. A Plus Biotechnology Co's current Scaled Net Operating Assets is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.30 — trading 14.7% below its estimated fair value. The current Scaled Net Operating Assets is 0.49. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Scaled Net Operating Assets is 0.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.30 is trading 14.7% below its estimated GF Value™ of NT$87.15.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
Scaled Net Operating Assets: 0.49
GF Value™: NT$87.15 vs. price of NT$74.30 (14.7% below fair value)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score
Get the complete analysis for TPE:6918
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
